Leap Therapeutics (Nasdaq: LPTX) is discontinuing the development of its anti-DKK1 antibody sirexatamab in gastric cancer after the drug failed to improve survival in a Phase II trial.
However, positive results from a separate mid-stage colorectal cancer study have prompted the company to begin planning for a Phase III trial in that indication.
The announcement came as Leap released initial data from two trials - Part B of the DeFianCe study in colorectal cancer and Part C of the DisTinGuish study in gastric cancer. While the former study showed improved response rates with sirexatamab, the DisTinGuish data were inconsistent.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze